p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis.
p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis.
复制标题
DOI：
10.1016/j.ctrv.2008.10.005
复制
发表时间：
2009-05
影响因子：
11.8
通讯作者：
Paraskevaidis, E.
中科院分区：
文献类型：
--
作者：
Tsoumpou, I.;Arbyn, M.;Kyrgiou, M.;Wentzensen, N.;Koliopoulos, G.;Martin-Hirsch, P.;Malamou-Mitsi, V.;Paraskevaidis, E.
P16INK4a is a biomarker for transforming HPV infections that could act as an adjunct to current cytological and histological assessment of cervical smears and biopsies, allowing the identification of those women with ambiguous results that require referral to colposcopy and potentially treatment. We conducted a systematic review of all studies that evaluated the use of p16INK4a in cytological or histological specimens from the uterine cervix. We also estimated the mean proportion of samples that were positive for p16INK4a in cytology and histology, stratified by the grade of the lesion. Sixty-one studies were included. The proportion of cervical smears overexpressing p16INK4a increased with the severity of cytological abnormality. Among normal smears, only 12% (95% CI: 7–17%) were positive for the biomarker compared to 45% of ASCUS and LSIL (95% CI: 35–54% and 37– 57% respectively) and 89% of HSIL smears (95% CI: 84–95%). Similarly, in histology only 2% of normal biopsies (95% CI: 0.4– 30%) and 38% of CIN1 (95% CI: 23– 53%) showed diffuse staining for p16INK4a compared to 68% of CIN2 (95% CI: 44– 92%) and 82% of CIN3 (95% CI: 72– 92%). Although there is good evidence that p16INK4a immunostaining correlates with the severity of cytological/histological abnormalities, the reproducibility is limited due to insufficiently standardized interpretation of the immunostaining. Therefore, a consensus needs to be reached regarding the evaluation of p16INK4a staining and the biomarker needs to be evaluated in various clinical settings addressing specific clinical questions.
登录
查看更多内容
影响因子：
5.6
作者：
Ansari-Lari, MA;Staebler, A;Ronnett, BM
通讯作者：
Ronnett, BM
DOI：
10.1097/01.pgp.0000139639.79105.40
发表时间：
2004-10-01
影响因子：
2.4
作者：
Branca, M;Ciotti, M;Syrjänen, K
通讯作者：
Syrjänen, K
影响因子：
1.3
作者：
Bose, S;Evans, H;Youssef, E
通讯作者：
Youssef, E
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N
影响因子：
3.4
作者：
Carozzi, F;Cecchini, S;Ciatto, S
通讯作者：
Ciatto, S